EPRX
Eupraxia Pharmaceuticals' second quarter 2026 EPS beat estimates as liquidity reached $133.7M
Eupraxia Pharmaceuticals reported a net loss of $14.5 million for the second quarter of 2026, outperforming analyst expectations for the period. As a...
